- Home
- LRHC vs VRAX Comparison
LRHC vs VRAX Comparison
Compare LRHC & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRHC | VRAX |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.9M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LRHC | VRAX |
|---|---|---|
| Price | $1.15 | $0.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 317.7K | ★ 15.3M |
| Earning Date | 11-19-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,660,186.00 | $2,986.00 |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.52 | N/A |
| 52 Week Low | $1.05 | $0.35 |
| 52 Week High | $95.20 | $3.20 |
Technical Indicators
Market Signals| Indicator | LRHC | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 21.66 | 47.64 |
| Support Level | $1.05 | $0.43 |
| Resistance Level | $2.25 | $0.87 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 5.00 | 19.37 |
Price Performance
Historical ComparisonAbout LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).